Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2661
Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2008
Creighton University School of MedicineClass of 2005
Certifications & Licensure
TX State Medical License 2009 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsBeat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Fieke W Hoff, William G Blum, Ying Huang, Rina Li Welkie, Ronan T Swords
Blood Advances. 2024-10-22 - 9 citationsA study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Sheng F Cai, Ying Huang, Jennie R Lance, Hsiaoyin Charlene Mao, Andrew J Dunbar
Blood Advances. 2024-01-23 - 19 citationsOral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan
The Lancet. Haematology. 2024-01-01
Abstracts/Posters
- Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant AbstractPrapti A. Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master TrialPrapti A. Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...Prapti A. Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Dr. Patel on the Role of Gilteritinib in FLT3+ AMLFebruary 17th, 2020- Targeted Therapy Shifts AML Paradigm, but More Work Lies AheadJanuary 28th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
